About Viking Therapeutics, Inc.
https://www.vikingtherapeutics.comViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
CEO
Brian Lian
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 136
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Truist Securities
Buy
Maxim Group
Buy
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10M
Value:$328.91M
BLACKROCK INC.
Shares:6.03M
Value:$198.22M
FMR LLC
Shares:5.79M
Value:$190.46M
Summary
Showing Top 3 of 427
About Viking Therapeutics, Inc.
https://www.vikingtherapeutics.comViking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $98.56M ▲ | $-90.79M ▼ | 0% | $-0.81 ▼ | $-98.45M ▼ |
| Q2-2025 | $0 | $74.57M ▲ | $-65.56M ▼ | 0% | $-0.58 ▼ | $-74.46M ▼ |
| Q1-2025 | $0 | $55.47M ▲ | $-45.63M ▼ | 0% | $-0.41 ▼ | $-55.36M ▼ |
| Q4-2024 | $0 | $46.24M ▲ | $-35.42M ▼ | 0% | $-0.32 ▼ | $-46.13M ▼ |
| Q3-2024 | $0 | $36.56M | $-24.94M | 0% | $-0.22 | $-36.47M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $714.57M ▼ | $739.41M ▼ | $26.39M ▼ | $713.03M ▼ |
| Q2-2025 | $807.72M ▼ | $827.85M ▼ | $32.39M ▲ | $795.46M ▼ |
| Q1-2025 | $851.86M ▼ | $866.99M ▼ | $20.07M ▼ | $846.92M ▼ |
| Q4-2024 | $902.61M ▼ | $908.32M ▼ | $28.04M ▲ | $880.28M ▼ |
| Q3-2024 | $930.44M | $937.89M | $26.44M | $911.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-90.79M ▼ | $-94M ▼ | $160.03M ▲ | $480K ▼ | $66.5M ▲ | $-94M ▼ |
| Q2-2025 | $-65.56M ▼ | $-47.06M ▲ | $42.51M ▼ | $507K ▲ | $-4.06M ▼ | $-47.06M ▲ |
| Q1-2025 | $-45.63M ▼ | $-52.33M ▼ | $63.24M ▲ | $349K ▼ | $11.26M ▲ | $-52.33M ▼ |
| Q4-2024 | $-35.42M ▼ | $-31.18M ▼ | $6.58M ▼ | $1M ▼ | $-23.67M ▼ | $-31.18M ▼ |
| Q3-2024 | $-24.94M | $-21.96M | $25.9M | $2.52M | $6.43M | $-21.96M |
CEO
Brian Lian
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 136
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
BTIG
Buy
Truist Securities
Buy
Maxim Group
Buy
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:10M
Value:$328.91M
BLACKROCK INC.
Shares:6.03M
Value:$198.22M
FMR LLC
Shares:5.79M
Value:$190.46M
Summary
Showing Top 3 of 427